Igc Pharma Inc. has reported additional results of preclinical studies investigating TGR-63, a potential treatment for Alzheimer’s disease. TGR-63 is designed to disrupt the structure of the amyloid-β (Aβ) peptide, one of the key hallmarks of Alzheimer’s.